Question follow-through · 64681
Prostate Cancer: Hormone Treatments
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 2 Jul 2025
- Target answer date
- 4 Jul 2025
- Answer
- 9 Jul 2025 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Ambulance Services: Mental Health Services · 9 Jul 2025
- Innovation: Beer and Public Houses · 9 Jul 2025
- Prostate Cancer: Hormone Treatments · 16 Jul 2025
- Radiotherapy · 18 Jul 2025
- Radiotherapy: Medical Equipment · 18 Jul 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
2 Jul 2025
Question tabled
To ask the Secretary of State for Health and Social Care, with reference to the randomised control trial study report entitled Cost utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long term hormone therapy in newly diagnosed
4 Jul 2025
Target answer date
Date supplied by the official written-questions record.
9 Jul 2025
Answer published
NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Ambulance Services: Mental Health Services
9 Jul 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of adequacy of the (a) support available to ambulance staff who attend traumatic callouts and (b) suicide prevention training provided to ambulance staff.
Innovation: Beer and Public Houses
9 Jul 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of innovation in the beer and pub sector with the (a) development and (b) availability of (i) no and (ii) low alcohol products on the aims of the
Prostate Cancer: Hormone Treatments
16 Jul 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 July 2025 to Question 64682 on Prostate Cancer: Hormone Treatments, if his Department will publish the Equality and Health Inequalities Impact Assessment for abirateron
Radiotherapy
18 Jul 2025 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a national radiotherapy advisory group.
Radiotherapy: Medical Equipment
18 Jul 2025 · To ask the Secretary of State for Health and Social Care, if he will take steps to include policies on replacing older radiotherapy machines in the national cancer plan.
Prostate Cancer: Hormone Treatments
1 Sept 2025 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 July 2025 to Question 64681 on Prostate Cancer: Hormone Treatments, for what reason recurrent headroom in revenue budgets is considered a barrier to implementing the abi
Clinical Priorities Advisory Group
11 Sept 2025 · To ask the Secretary of State for Health and Social Care, whether the Clinical Priorities Advisory Group has a budget to approve new treatments.
Medical Treatments
10 Oct 2025 · To ask the Secretary of State for Health and Social Care, whether there is a facility for the NHS to approve treatments without external payment for assessment by the National Institute for Health and Care Excellence.
Rare Cancers: Diagnosis
14 Oct 2025 · To ask the Secretary of State for Health and Social Care, how the full roll-out of the non-specific symptom pathways is being measured; and how their development has included the less survivable cancers.
Rare Cancers: Medical Treatments
14 Oct 2025 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of minimally invasive therapies for the less survivable cancers.
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of men in England with newly diagnosed high-risk, non-metastatic prostate cancer who would be eligible for abiraterone under the eligibility crit
Abiraterone
17 Oct 2025 · To ask the Secretary of State for Health and Social Care, if he will make an estimate of the potential impact of prescribing abiraterone in England using the eligibility criteria used in (a) Scotland and (b) Wales on the number of premature deaths from hi